Our Approach
Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.
Pipeline
The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.
Clinical Trials
We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.
News
ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering
6 September 2019
ADC Therapeutics Files Registration Statement for Proposed Initial Public OfferingLausanne, Switzerland — September 6, 2019 — ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a
ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
26 August 2019
ADC Therapeutics and Freenome Enter Biomarker Development CollaborationADC Therapeutics to employ Freenome’s multiomics platform to identify biomarkers that correlate with clinical response to ADCT-402 (loncastuximab tesirine) LAUSANNE, Switzerland and SOUTH SAN FRANCISCO, Calif., August 26, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
6 August 2019
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical TrialStudy to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Lausanne, Switzerland, August 6, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and SOPHiA GENETICS, a leader in Data-Driven Medicine,
